Market Research Logo

Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)

Global Hemophilia Market Report: Insights, Trends and Forecast (2019-2023)

The global hemophilia market is estimated to reach US$12.98 billion in 2023, holding a CAGR of 6.21% in the duration spanning 2018-2023. The factors such as rise in diagnoses rate of hemophilia, rise in global healthcare expenditure and shifting focus to extended half-life (EHL) therapies are expected to drive the growth of the global hemophilia market. However, growth of the industry will be challenged by high price of treatment and reluctance to switch to new therapies. A few notable trends include shifting focus to Extended Half Life (EHL) therapies, development of novel hemophilia treatments and popularity of gene therapy.

The global hemophilia market comprises of two major segments: hemophilia A and hemophilia B. hemophilia A is four time prevalent than hemophilia B. The growing incidences of hemophilia A at vast rate has driven the increased demand for anti-hemophilia A or clotting factor VIII drugs. The pharmaceutical industry is flooded with drugs to be used in the treatment of type A, and thereby providing scope for the expansion of the global hemophilia market.

The fastest growing regional market in the hemophilia space is the U.S. due to High prevalence of hemophilia, coupled with rising inclination toward prophylaxis treatment. Rise in the population of hemophilia patients, is augmenting the need for more significant treatment methods. A lot of anti-hemophilia products are available in the market and several drugs are still in their late stage clinical process by large pharmaceutical firms. Furthermore, The U.S. and Europe are the highly established premium markets that contribute to considerable shares in the global hemophilia market.

Scope of the report:

  • The report provides a comprehensive analysis of the global hemophilia market, segmented into hemophilia A and hemophilia B.
  • The major regional markets (the U.S. and Europe) have been analyzed.
  • The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
  • The competitive landscape of the market, along with the company profiles of leading players (Pfizer Inc., Bayer Group, Sanofi S.A., Takeda Pharmaceutical Company, Novo Nordisk and CSL Limited) are also presented in detail.
Key Target Audience:
  • Hemophilia Drugs Manufacturers
  • Raw Material Suppliers
  • End Users (Hospital, Medical centers, Clinical Institutes)
  • Healthcare Consulting Firms
  • Investment Banks
  • Government Bodies & Regulating Authorities


1. Market Overview
1.1 Hemophilia
1.2 Types of Hemophilia
Table 1: Types of Hemophilia
1.3 Signs & Symptoms
Table 2: Signs & Symptoms of Hemophilia
1.4 Diagnosis of Hemophilia
Table 3: Diagnosis of Hemophilia
1.5 Treatment of Hemophilia
2. Global Market Analysis
2.1 Global Hemophilia Market by Value
Table 4: Global Hemophilia Market by Value (2014-2018)
2.2 Global Hemophilia Market Forecast by Value
Table 5: Global Hemophilia Market Forecast by Value (2019-2023)
2.3 Global Hemophilia Market by Treatment Regimen
Table 6: Global Hemophilia Market by Treatment Regimen (2018)
2.4 Global Hemophilia Market by Type
Table 7: Global Hemophilia Market by Type (2018)
2.4.1 Global Hemophilia A Market Forecast by Value
Table 8: Global Hemophilia A Market Forecast by Value (2018-2023)
2.4.2 Global Hemophilia A Market by Severity
Table 9: Global Hemophilia A Market by Severity (2018)
2.4.3 Global Hemophilia A Market by Treatment Type
Table 10: Global Hemophilia A Market by Treatment Type (2018)
2.4.4 Global Hemophilia A Market by Treatment Regimen
Table 11: Global Hemophilia A Market by Treatment Regimen (2018)
2.4.5 Global Hemophilia B Market Forecast by Value
Table 12: Global Hemophilia B Market Forecast by Value (2018-2023)
2.4.6 Global Hemophilia B Market by Severity
Table 13: Global Hemophilia B Market by Severity (2018)
2.4.7 Global Hemophilia B Market by Treatment Type
Table 14: Global Hemophilia B Market by Treatment Type (2018)
2.4.8 Global Hemophilia B Market by Treatment Regimen
Table 15: Global Hemophilia B Market by Treatment Regimen (2018)
3. Regional Market Analysis
3.1 The U.S.
3.1.1 The U.S. Hemophilia Market by Value
Table 16: The U.S. Hemophilia Market by Value (2014-2018)
3.1.2 The U.S. Hemophilia Market Forecast by Value
Table 17: The U.S. Hemophilia Market Forecast by Value (2019-2023)
3.1.3 The U.S. Hemophilia Market by Type
Table 18: The U.S. Hemophilia Market by Type (2018)
3.1.4 The U.S. Hemophilia A Market Forecast by Value
Table 19: The U.S. Hemophilia A Market Forecast by Value (2018-2023)
3.1.5 The US Hemophilia A Market-Treated Patient Volume Forecast
Table 20: The U.S. Hemophilia A Market-Treated Patient Volume Forecast (2018-2023)
3.1.6 The US Hemophilia A Market-Severe Patients on Prophylactic Therapy
Table 21: The U.S. Hemophilia A Market-Severe Patients on Prophylactic Therapy (2018-2023)
3.1.7 The US Hemophilia A Market-Severe Patients on On-Demand Therapy
Table 22: The U.S. Hemophilia A Market-Severe Patients on On-Demand Therapy (2018-2023)
3.1.8 The US Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy
Table 23: The U.S. Hemophilia A Market-Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
3.1.9 The US Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy
Table 24: The U.S. Hemophilia A Market-Mild to Moderate Patients on On-Demand Therapy (2018-2023)
3.1.10 The US Hemophilia B Market Forecast by Value
Table 25: The U.S. Hemophilia B Market Forecast by Value (2018-2023)
3.1.11 The US Hemophilia B Market- Treated Patients Volume Forecast
Table 26: The U.S. Hemophilia B Market- Treated Patients Volume Forecast (2018-2023)
3.1.12 The US Hemophilia B Market- Severe Patients on Prophylaxis Therapy
Table 27: The U.S. Hemophilia B Market- Severe Patients on Prophylaxis Therapy (2018-2023)
3.1.13 The US Hemophilia B Market- Severe Patients on On-Demand Therapy
Table 28: The U.S. Hemophilia B Market- Severe Patients on On-Demand Therapy (2018-2023)
3.1.14 The US Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy
Table 29: The U.S. Hemophilia B Market- Mild to Moderate Patients on Prophylaxis Therapy (2018-2023)
3.1.15 The US Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy
Table 30: The U.S. Hemophilia B Market- Mild to Moderate Patients on On-Demand Therapy (2018-2023)
3.2 Europe
3.2.1 Europe’s Hemophilia Market- Patient Volume Forecast
Table 31: Europe’s Hemophilia Market- Patient Volume Forecast (2018-2023)
3.2.2 Europe’s Hemophilia A Market- Patient Volume Forecast
Table 32: Europe’s Hemophilia A Market- Patient Volume Forecast (2018-2023)
3.2.3 Europe’s Hemophilia B Market- Patient Volume Forecast
Table 33: Europe’s Hemophilia B Market- Patient Volume Forecast (2018-2023)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increased Focus on Prophylactic Treatment
Table 34: Global Market Share of Hemophilia A and B Patients on Prophylaxis (2018)
4.1.2 Increasing Diagnosis Rate
Table 35: Global Identified Hemophilia Patients Volume (2011-2018)
4.1.3 Rise in Global Healthcare Expenditure
Table 36: Global Healthcare Expenditure (2014-2018)
4.2 Key Trends & Development
4.2.1 Shifting Focus to Extended Half Life Therapies
Table 37: Extended Half Life Products (2018)
4.2.2 Development of Novel Hemophilia Treatments
Table 38: Development of New Novel Hemophilia Treatments (2018)
4.2.3 Popularity of Gene Therapy
Table 39: Hemophilia Gene Therapy Candidates (2018)
4.3 Challenges
4.3.1 High Cost of Treatment
4.3.2 Reluctance to Switch to New Therapies
5. Competitive Landscape
5.1 The Global Market
5.1.1 Global Hemophilia A Market Share by Company
Table 40: Global Hemophilia A Market Share by Company (2018)
5.1.2 Global Hemophilia A Factor VIII Products Market Share by Company
Table 41: Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
5.1.3 Global Hemophilia A FVIII Gene Therapy Market Share Forecast
Table 42: Global Hemophilia A Factor VIII Products Market Share by Company (2023/2030)
5.1.4 Global Hemophilia B Market Share by Company
Table 43: Global Hemophilia B Market Share by Company (2018)
5.1.5 Global Hemophilia B Factor IX Products Market Share Forecast
Table 44: Global Hemophilia B Factor IX Products Market Share Forecast (2023/2030)
5.1.6 Global Hemophilia B Factor IX Gene Therapy Market Share Forecast
Table 45: Global Hemophilia B Factor IX Gene Therapy Market Share Forecast (2030)
5.1.7 Key Players – Main Anti-Hemophilia Products
Table 46: Key Players – Main Anti-Hemophilia Products
5.1.8 Key Players – Revenue Comparison
Table 47: Key Players – Revenue Comparison (2018)
5.1.9 Key Players – Market Capital Comparison
Table 48: Key Players – Market Cap Comparison (2018)
5.2 The U.S. Market
The U.S. Hemophilia A Market Share by Company
Table 49: The U.S. Hemophilia A Market Share by Company (2018)
5.3 Europe Market
Europe Hemophilia A Market Share by Company
Table 50: Europe Hemophilia B Market Share by Company (2018)
6. Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Overview
Table 51: Pfizer Inc. Revenue Share by Major Business Segment (2018)
6.1.2 Financial Overview
Table 52: Pfizer Inc. Revenue and Net Income (2014-2018)
6.1.3 Business Strategies
Table 53: Major Products Developed by Pfizer Inc. (2018)
Table 54: Pfizer Inc. R&D Expenses (2016-2018)
6.2 Bayer Group
6.2.1 Business Overview
Table 55: Bayer Group Net Sales Share by Business Segments (2018)
6.2.2 Financial Overview
Table 56: Bayer Group Net Sales and Net Income (2014-2018)
6.2.3 Business Strategies
Table 57: Major Products Developed by Bayer Group (2018)
Table 58: Bayer Group R&D Expenses (2016-2018)
6.3 Sanofi S.A.
6.3.1 Business Overview
Table 59: Sanofi S.A. Revenue Share by Segments (2018)
6.3.2 Financial Overview
Table 60: Sanofi S.A. Net Sales and Net Income (2014-2018)
6.3.3 Business Strategies
Table 61: Sanofi S.A. R&D Expenses (2016-2018)
6.4 Takeda Pharmaceutical Company
6.4.1 Business Overview
Table 62: Takeda Pharmaceutical Company Revenue Share by Region (2019)
6.4.2 Financial Overview
Table 63: Takeda Pharmaceutical Company Revenue and Net Income (2015-2019)
6.4.3 Business Strategies
Table 64: Takeda Pharmaceutical Company R&D Expenses (2017-2019)
6.5 Novo Nordisk
6.5.1 Business Overview
Table 65: Novo Nordisk Net Sales Share by Business Segments (2018)
6.5.2 Financial Overview
Table 66: Novo Nordisk Net Sales and Net Profit (2014-2018)
6.5.3 Business Strategies
Table 67: Novo Nordisk R&D Expenses (2016-2018)
Table 68: Novo Nordisk Product Pipeline (2018)
6.6 CSL Limited
6.6.1 Business Overview
Table 69: CSL Limited Revenue Share by Segments (2018)
6.6.2 Financial Overview
Table 70: CSL Limited Sales Revenue and Net Profit (2014-2019)
6.6.3 Business Strategies
Table 71: CSL Limited R&D Expenses (2016-2018)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report